NIH Clinical Center Search the Studies: Study Number, Study Title

Protocol Details

Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy Subjects for the Expansion of T Cells for Adoptive Cell Therapy

This study is currently recruiting participants.

Summary | Eligibility | Citations | Contacts

Summary

Number

16-C-0138

Sponsoring Institute

National Cancer Institute (NCI)

Recruitment Detail

Type: Participants currently recruited/enrolled
Gender: Male & Female
Min Age: 18 Years
Max Age: 120 Years

Referral Letter Required

No

Population Exclusion(s)

Pregnant Women;
Fetuses;
Children

Keywords

Normal Volunteer;
Donation;
Adoptive T Cell Therapies;
Peripheral Blood Mononuclear Cells;
Natural History

Recruitment Keyword(s)

None

Condition(s)

Healthy Volunteer

Investigational Drug(s)

None

Investigational Device(s)

None

Intervention(s)

None

Supporting Site

National Cancer Institute

Title: Collection of Peripheral Blood Mononuclear Cells (PBMCs) from Healthy People for the Expansion of T Cells for Adoptive Cell Therapy

Background:

New therapies are being developed that use a person s own immune system to fight tumors. Some of the tumors being studied include cancers caused by viruses. Researchers want to use the healthy cells of volunteers to perform research studies. To do this, they are collecting lymphocytes through leukapheresis.

Objectives:

To collect healthy cells from volunteers for research studies for new cancer therapies.

Eligibility:

Healthy people ages 18 and older

Design:

Participants will be screened with a standard donor questionnaire. It asks about their health and past medical problems. It also asks about risky behaviors that could increase their exposure to viruses or bacteria that could be transmitted through a transfusion. Participants will give a blood sample to make sure they are able to donate. They will have a physical exam. A finger stick test will check their hemoglobin, or red blood cell, level. They might give a urine sample.

Participants will undergo apheresis. For this, a needle is placed in a vein in each of their arms. Their blood is taken from one arm. A machine separates the white cells from the red cells and plasma by a spinning process. The white cells are removed and directed into a plastic bag. The red cells and plasma are returned through the needle in the other arm. The entire procedure takes 4 6 hours.

Participants may donate every 21 days in this protocol if they choose to.

--Back to Top--

Eligibility

INCLUSION CRITERIA:

-Age greater than or equal to 18 years old and able to give consent.

-Adequate clinical parameters (all of the following):

--Afebrile (temperature less than or equal to 37.5 degree C)

--Systolic blood pressure less than or equal to180 mmHg

--Diastolic blood pressure less than or equal to100 mmHg

--Weight greater than or equal to 110 lbs.

--Heart rate between 50-100 beats/minute

--Adequate bilateral antecubital venous access for a 2 arm apheresis procedure

-Females of child-bearing potential should not be pregnant or breast-feeding.

-Within 30 days of pheresis donation, donors must be negative for infectious disease work-up: Antibody screen for Hepatitis B, Hepatitis C; HIV, HTLV-I/II, T. cruzi (Chagas agent), West Nile, and syphilis (RPR)

-Within 30 days of pheresis donation, donor must have:

--Hemoglobin:

---Women greater than or equal to 12.5 gm/dL

---Men greater than or equal to 13.0 gm/dL

--Platelets greater than or equal to 100,000/microliter

--Total WBC greater than or equal to 2 K/microliter

EXCLUSION CRITERIA:

-History of medical illness that in the estimation of the PI or DTM physician precludes donation of PBMCs.

-Current psychiatric diagnosis that would compromise compliance with donation or precludes appropriate informed consent.

-Presence of any blood transmissible infectious disease that cannot be cleared prior to PBMC donation and poses an unacceptable risk for the recipient.

-Active malignancy will exclude the donor. Any history of malignancy will be considered on a case by case basis in accordance with NIH/DTM criteria.

-If the participant answers Yes to any initial screening question, the participant will be considered ineligible.

-If the participant is deferred according to DTM Cellular Therapy Screening Standard Operating Procedures (SOP), the participant will be considered ineligible.


--Back to Top--

Citations:

Not Provided

--Back to Top--

Contacts:

Principal Investigator

Referral Contact

For more information:

Scott M. Norberg, D.O.
National Cancer Institute (NCI)
NIHBC 10 - CLINICAL CENTER BG RM 13N240
10 CENTER DR
BETHESDA MD 20892
(301) 275-9668
scott.norberg@nih.gov

Laura A. Parsons-Wandell, R.N.
National Cancer Institute (NCI)
National Institutes of Health
Building 10
Room 4-3140
10 Center Drive
Bethesda, Maryland 20892
(240) 858-7480
laura.parsons-wandell@nih.gov

NCI Referral Office
National Institute of Health Clinical Center (CC), 9000 Rockville Pike, Bethesda, Maryland 20892, United States: NCI Clinical Trials Referral Office
1-888-NCI-1937

Clinical Trials Number:

NCT02821806

--Back to Top--